Key result
Telmisartan improves insulin resistance and increases adiponectin in hypertension to mitigate CV complications.
Telmisartan may offer benefits in patients with arterial hypertension by improving insulin resistance and increasing adiponectin levels.
Telmisartan may boost adiponectin defense in insulin-resistant hypertension; leaves open outcome benefits versus other ARBs in trials.
In the current paradigm, the primary insulin resistance plays a central role in the development of not only diabetes but also associated with cardiovascular complications, such as arterial hypertension, arteriosclerosis, heart failure, atrial fibrillation. Defense mechanism involves the secretion of adiponectin from adipoctyes and thus helps to block the development of these diseases. Modern antihypertensive treatment options of angiotensin-receptor blocker telmisartan show that, telmisartan can be used in patients with arterial hypertension because of improving insulin resistance and increasing adiponectin levels.
No takes yet. Share an insight, caveat, or question.
В Н Шишкова (2014) conducted a review in Cardiovascular disease and type 2 diabetes. Telmisartan was evaluated. Telmisartan improves insulin resistance and increases adiponectin levels in patients with arterial hypertension, offering a mechanism to mitigate cardiovascular complications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: